Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYRO3 | Q06418 | 16/20 | 0.38 |
| ▸ | MERTK | Q12866 | 15/20 | 0.38 |
| ▸ | FLT3 | P36888 | 14/20 | 0.38 |
| ▸ | GAS6 | Q14393 | 13/20 | 0.38 |
| ▸ | AXL | P30530 | 4/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.36 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.36 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3961604 | 0.92 | AXL (0.38) | TYRO3MERTKFLT3GAS6AXL | |
| SCHEMBL4090204 | 0.90 | MERTK (0.41) | TYRO3MERTKFLT3GAS6AXL | |
| Hydrochloric Acid SCHEMBL3965512 | 0.89 | MERTK (0.40) | TYRO3MERTKFLT3GAS6AXL | |
| SCHEMBL3965641 | 0.87 | MERTK (0.39) | TYRO3MERTKFLT3GAS6AXL | |
| SCHEMBL3964769 | 0.86 | FGFR1 (0.45) | TYRO3MERTKFLT3GAS6AXL | |
| Hydrochloric Acid SCHEMBL3958567 | 0.86 | FGFR1 (0.45) | TYRO3MERTKFLT3GAS6AXL | |
| Hydrochloric Acid SCHEMBL3965367 | 0.86 | FGFR1 (0.45) | TYRO3MERTKFLT3GAS6AXL | |
| Hydrochloric Acid SCHEMBL3965328 | 0.85 | FLT3 (0.38) | TYRO3MERTKFLT3GAS6AXL | |
| SCHEMBL3964338 | 0.85 | TYRO3 (0.43) | TYRO3MERTKFLT3GAS6AXL | |
| SCHEMBL3966411 | 0.85 | TYRO3 (0.39) | TYRO3MERTKFLT3GAS6AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1989200-B1 | [4-(BENZO[B]THIOPHEN-2-YL)-PYRIMIDIN-2-YL]-AMINE DERIVATIVES AS IKK-BETA INHIBITORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASES | LILLY CO ELI (US) | 2009-07-29 | — | — | EP | disclosed |
| US-7547691-B2 | [4-(Benzo[B]thiophen-2-yl) Pyrimidin-2-yl]-amine derivatives as IKK-beta inhibitors for the treatment of cancer and inflammatory diseases | ELI LILLY AND COMPANY (US) | 2009-06-16 | — | — | US | disclosed |
| US-20080306082-A1 | [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases | ELI LILLY AND COMPANY | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306082-A1 | [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases | NFKBIA, IKBKB, IKBKG | TYRO3 456/4885MERTK 802/4885FLT3 706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.